Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 4/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335229 | 0.89 | SIGMAR1 (0.40) | SIGMAR1CCR5CFTRADRB2MAPT | |
| SCHEMBL2334473 | 0.87 | CFTR (0.39) | SIGMAR1CFTRADRB2 | |
| SCHEMBL2331440 | 0.85 | SIGMAR1 (0.39) | SIGMAR1CCR5CFTRADRB2MAPT | |
| SCHEMBL12156814 | 0.82 | SMN1; SMN2 (0.45) | SIGMAR1CCR5CFTRADRB2KDM4E | |
| Hydrochloric Acid SCHEMBL2337786 | 0.81 | KDM4E (0.44) | SIGMAR1CCR5CFTRADRB2KDM4E | |
| SCHEMBL12156820 | 0.81 | KDM4E (0.41) | SIGMAR1CCR5CFTRADRB2KDM4E | |
| Hydrochloric Acid SCHEMBL2331840 | 0.80 | KDM4E (0.41) | SIGMAR1CCR5CFTRADRB2KDM4E | |
| SCHEMBL12156798 | 0.79 | PIK3CD (0.42) | SIGMAR1CCR5CFTRADRB2KDM4E | |
| SCHEMBL2337744 | 0.79 | MEN1 (0.42) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2336543 | 0.78 | PIK3CD (0.42) | SIGMAR1CCR5CFTRADRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048884-B2 | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2188268-B1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2188268-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100075976-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
| WO-2009029439-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075976-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | SIGMAR1 291/4885CCR5 408/4885CFTR 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.